Key result
Treatment linked to ~9% lower homocysteine in a 21-year-old presenting with subclavian vein thrombosis.
Why the study?
The association between hyperhomocysteinemia and venous thrombosis has been controversial but is now widely confirmed, necessitating further clinical awareness and investigation.
Case Report (n=1)
Hyperhomocysteinemia should be investigated as part of the thrombophilia assessment in patients presenting with venous thrombosis.
May support hyperhomocysteinemia evaluation in atypical venous thrombosis; leaves open validation in larger cohorts.
Case ReportThe association between hyperhomocysteinemia and venous thrombosis, which has been controversial for a long time, is now widely confirmed.The causes of hyperhomocysteinemia are multiple, both hereditary and acquired.The most common hereditary abnormality is the C677T mutation of methylenetetrahydrofolate reductase (MTHFR) in a heterozygote state.Hyperhomocysteinemia is a risk factor for venous thrombosis that should be investigated as part of the Thrombophilia assessment.The observation of a 21 year old patient with hyperhomocysteinemia diagnosed by a thrombosis of the subclavian vein will be reported first, then the role of this abnormality in the occurrence of arterial and venous thrombotic incidents will be recalled.
No takes yet. Share an insight, caveat, or question.
T et al. (2020) conducted a case report in Subclavian vein thrombosis and hyperhomocysteinemia (n=1). Sintrom was evaluated on Homocysteine level. A 21-year-old patient presenting with subclavian vein thrombosis was diagnosed with hyperhomocysteinemia, which improved from 15.78 to 14.40 micromol/L after two months of treatment.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: